Literature DB >> 27928356

Autoimmune-Related Retinopathy and Optic Neuropathy Accompanied by Anti-GAD Antibodies.

Sumayya J Almarzouqi1, Michael L Morgan1, Petros E Carvounis2, Andrew G Lee3.   

Abstract

Autoimmune-related retinopathy and optic neuropathy is characterized by visual loss in the presence of antibodies against retina or optic nerve antigens in the absence of neoplasia. We report a case with progressive central visual loss accompanied by latent autoimmune diabetes in an adult. Visual fields, multimodal imaging and electrophysiological testing showed characteristic changes without evidence of neoplasia on positron emission tomography. Immunologic testing revealed abnormal reactivity against a 20 kDa optic nerve antigen and 40 kDa and 62 kDa retina antigens along with antibodies against anti-glutamic acid decarboxylase, a constellation which we believe to be unique.

Entities:  

Keywords:  ARRON; Anti-GAD; autoimmune optic neuropathy; autoimmune retinopathy; optic nerve autoantibody; retinal autoantibody

Year:  2015        PMID: 27928356      PMCID: PMC5123164          DOI: 10.3109/01658107.2015.1050744

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN: 0165-8107


  13 in total

1.  Cone dysfunction as a paraneoplastic syndrome associated with retinal antigens approximating 40 kiloDalton.

Authors:  Christine E Parc; Elodie Azan; Sébastien Bonnel; José Alain Sahel; Josseline Kaplan; Charles E Thirkill
Journal:  Ophthalmic Genet       Date:  2006-06       Impact factor: 1.803

2.  Immune-mediated retinopathy in a patient with stiff-man syndrome.

Authors:  H Steffen; N Menger; W Richter; B Nölle; H Krastel; C Stayer; G H Kolling; H Wässle; H M Meinck
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1999-03       Impact factor: 3.117

3.  Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies.

Authors:  Richard G Weleber; Robert C Watzke; William T Shults; Karmen M Trzupek; John R Heckenlively; Robert A Egan; Grazyna Adamus
Journal:  Am J Ophthalmol       Date:  2005-05       Impact factor: 5.258

Review 4.  Autoimmune retinopathy.

Authors:  Landon Grange; Monica Dalal; Robert B Nussenblatt; H Nida Sen
Journal:  Am J Ophthalmol       Date:  2013-09-29       Impact factor: 5.258

5.  The cancer-associated retinopathy antigen is a recoverin-like protein.

Authors:  C E Thirkill; R C Tait; N K Tyler; A M Roth; J L Keltner
Journal:  Invest Ophthalmol Vis Sci       Date:  1992-09       Impact factor: 4.799

6.  A case of autoimmune-related retinopathy and optic neuropathy syndrome treated by autologous nonmyeloablative hematopoietic stem cell transplantation.

Authors:  Yu Oyama; Richard K Burt; Charles Thirkill; Eissa Hanna; Kevin Merrill; John Keltner
Journal:  J Neuroophthalmol       Date:  2009-03       Impact factor: 3.042

Review 7.  Autoimmune retinopathy: a review and summary.

Authors:  John R Heckenlively; Henry A Ferreyra
Journal:  Semin Immunopathol       Date:  2008-04-12       Impact factor: 9.623

Review 8.  Autoimmune retinopathy.

Authors:  Didar U Comlekoglu; Ian A Thompson; H Nida Sen
Journal:  Curr Opin Ophthalmol       Date:  2013-11       Impact factor: 3.761

9.  Recoverin, but not visinin, is an autoantigen in the human retina identified with a cancer-associated retinopathy.

Authors:  A S Polans; M D Burton; T L Haley; J W Crabb; K Palczewski
Journal:  Invest Ophthalmol Vis Sci       Date:  1993-01       Impact factor: 4.799

10.  Diversity in autoimmunity against retinal, neuronal, and axonal antigens in acquired neuro-retinopathy.

Authors:  Grazyna Adamus; Lori Brown; Jade Schiffman; Alessandro Iannaccone
Journal:  J Ophthalmic Inflamm Infect       Date:  2011-07-10
View more
  1 in total

1.  Management of Autoimmune Encephalitis: An Observational Monocentric Study of 38 Patients.

Authors:  Stefan Macher; Friedrich Zimprich; Desiree De Simoni; Romana Höftberger; Paulus S Rommer
Journal:  Front Immunol       Date:  2018-11-22       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.